Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy
Open Access
- 25 May 2020
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 14 (8) , 1719-1730
Abstract
As the use of next‐generation sequencing (NGS) for plasma cell‐free DNA (cfDNA) continues to expand in clinical settings, accurate identification of circulating tumor DNA mutations is important to validate its use in the clinical management for cancer patients. Here, we aimed to characterize mutations including clonal hematopoiesis (CH)‐related mutations in plasma cfDNA and tumor tissues using the same ultradeep NGS assay and evaluate the clinical significance of CH‐related mutations on the interpretation of liquid biopsy results. Ultradeep targeted NGS using Oncomine Pan‐Cancer Panel was performed on matched surgically resected tumor tissues, peripheral blood cells (PBCs), and 120 plasma cfDNA samples from 38 colorectal cancer patients. The clinical significance of the CH‐related mutations in plasma cfDNA was evaluated by longitudinal monitoring of the postoperative plasma samples. Among the 38 patients, 74 nonsynonymous mutations were identified from tumor tissues and 64 mutations from the preoperative plasma samples. Eleven (17%) of the 64 mutations identified in plasma cfDNA were also detected in PBC DNA and were identified to be CH‐related mutations. Overall, 11 of 38 (29%) patients in this cohort harbored at least one CH‐related mutation in plasma cfDNA. These CH‐related mutations were continuously detected in subsequent postoperative plasma samples from three patients which could be misinterpreted as the presence of residual disease or as lack of treatment response. Our results indicated that it is essential to integrate the mutational information of PBCs to differentiate tumor‐derived from CH‐related mutations in liquid biopsy analysis. This would prevent the misinterpretation of results to avoid misinformed clinical management for cancer patients.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP18K15332, JP18K15292)
- Council for Science, Technology and Innovation
This publication has 35 references indexed in Scilit:
- Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordanceAnnals of Oncology, 2017
- Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate CancerJNCI: Journal of the National Cancer Institute, 2017
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsNature Medicine, 2017
- Liquid biopsies come of age: towards implementation of circulating tumour DNANature Reviews Cancer, 2017
- Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNAOncotarget, 2016
- Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancerScience Translational Medicine, 2016
- Somatic mutations in leukocytes infiltrating primary breast cancersnpj Breast Cancer, 2015
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesScience Translational Medicine, 2014
- Intra-tumoral Heterogeneity ofKRASandBRAFMutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample TestingAnalytical Cellular Pathology, 2011